NCT06153849 is a clinical trial of urine sample collection in Bladder Cancer, sponsored by Changhai Hospital.

Who is sponsoring NCT06153849?

NCT06153849 is sponsored by Changhai Hospital.

What drugs are being tested in NCT06153849?

Interventions in NCT06153849: urine sample collection.

What condition does NCT06153849 study?

NCT06153849 studies Bladder Cancer.

Is NCT06153849 still recruiting?

NCT06153849 is currently status unknown. Last updated 1 December 2023.

Last reviewed 2023-12-01 · How we verify

NCT06153849

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Analyzing the Urine During BCG Instillation in Bladder Cancer Patients for Disease Followup

Status unknown Last updated 1 December 2023

What this trial tests

trial testing urine sample collection in Bladder Cancer in 100 participants. Status unknown.

Timeline

1 December 2023

Primary endpoint
1 December 2024

1 May 2025

Quick facts

Lead sponsor	Changhai Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	1 December 2023
Primary completion	1 December 2024
Estimated completion	1 May 2025
Sites	1 location across China

Drugs / interventions tested

urine sample collection — full drug profile →

Conditions studied

Bladder Cancer — all drugs for Bladder Cancer →

Sponsor

Changhai Hospital

Who can join

Adults 18 to 99, any sex, with Bladder Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Bacillus Calmette-Guerin (BCG) has been extensively utilized in intravesical instillation therapy for patients with medium to high risk non-muscle invasive bladder cancer (NMIBC) following transurethral resection of bladder tumor (TURBT). Nevertheless, the efficacy of BCG instillation can fluctuate between patients, with 40.5% experiencing disease recurrence during BCG therapy. The effectiveness of BCG instillation may be linked to the urinary microbiome and immune microenvironment. Additionally, small residual lesions post-TURBT could also result in bladder cancer recurrence. Low coverage whole genome sequencing (LC-WGS) can be used to detect the urinary microbiome and chromosomal instability (CIN), making it feasible to predict the recurrence or progression of bladder cancer during BCG instillation therapy. Here, we intend to evaluate the feasibility of detecting urine samples of bladder cancer patients receiving BCG instillation to predict the bladder cancer recurrence.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The Role of Tumor and Host Microbiome on Immunotherapy Response in Urologic Cancers.
Pfail J, Drobner J, Doppalapudi K, Saraiya B, et al · · 2024 · cited 6× · PMID 38846356 · DOI 10.33696/cancerimmunol.6.078
Decoding Microbiota in Genitourinary Oncology: Biological Mechanisms and Clinical Implications-A Narrative Review.
Caramella I, Abeni C, Cherri S, Ogliosi C, et al · · 2026 · PMID 41681968 · DOI 10.3390/cancers18030497

Verify or expand the search:

Other trials of urine sample collection

Trials testing the same drug.

NCT05893316 — UroCAD for Hematuria Evaluation--A Prospective, Multi-center Study · unknown
NCT05627713 — Clinical and Biological Aspects of the MONKEYPOX Disease · NA · recruiting
NCT04010682 — Late Pregnancy Sample Collection Study · completed

Other recruiting trials for Bladder Cancer

Currently open trials in the same condition.

NCT07419295 — A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) · Phase 3 · recruiting
NCT07322263 — Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC · Phase 2 · recruiting
NCT07420517 — Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer · Phase 2 · recruiting
NCT07475403 — Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer · Phase 2 · recruiting
NCT07277413 — A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors · Phase 1 · recruiting

Other Changhai Hospital trials

Trials by the same sponsor.

NCT07490002 — Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC · Phase 2 · not yet recruiting
NCT07464392 — FMT for the Prevention of Infectious Complications in Patients With Moderately Severe and Severe Acute Pancreatitis · NA · recruiting
NCT07507071 — Comparison of the Sensitivity of pCLE and Pathological Biopsy for Gastric Mucosal Lesions · not yet recruiting
NCT07481591 — Capsule Endoscopy in GI Bleeding: A Retrospective Study · not yet recruiting
NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06153849 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Changhai Hospital
Last refreshed: 1 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06153849.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing